Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, and NCI Supplied Veliparib (ABT-888) in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Who can apply: People diagnosed with recurring ovarian, primary peritoneal, or fallopian tube cancer.
Purpose: To determine the appropriate dose of an experimental drug, evaluate side effects when combined with other drugs, and test samples of tumor tissue (if available from a previous surgery or biopsy).
Drugs: ABT-888 (Veliparib), carboplatin and pegylated liposomal doxorubicin (PLD).
Number of participants: 10.